Generic name: Fingolimod Clinical Trial
See also: Clinical Trial
NCT00289978 is a completed 24-month, double-blind, randomized study comparing the efficacy and safety of fingolimod 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Other study names are ID#CFTY720D2301 and FREEDOMS.
|This item is relevant to you: Multiple sclerosis||1||0||
- Can't tell